TLM 2022 - SIG Programming

5 (2 votes)

Programming from TLM 2022 hosted by AASLD's Special Interest Groups. Programs include:

  • ACLF and Clinical Practice
  • ALD and NAFLD
  • Applications in Public Health
  • Cholestatic & Autoimmune and Liver Transplant
  • Hepatitis B
  • Hepatitis C
  • Hepatology Associates
  • Hepatotoxicity
  • Liver Cancer and Pediatrics
  • Liver Fibrosis
  • Pediatric Liver Disorders
  • Portal Hypertension

Key:

Complete
Failed
Available
Locked
Hepatitis B SIG Program: Navigating HBV treatment and cure by starting or stopping nucleos(t)ide analogues (NUC)
Hepatitis B SIG Program: Navigating HBV treatment and cure by starting or stopping nucleos(t)ide analogues (NUC)
Open to view video.  |  96 minutes
Open to view video.  |  96 minutes During this session the HBV SIG will address what the treatment indications are for HBV, and how to treat chronic HBV patients with NUC in the best way. During the second part of the session, we will address the pros and cons of NUC withdrawal
You must register to access.
Liver Cancer SIG and Pediatric Liver Disorders SIG Program: Pediatric Liver Cancers: From Mechanisms to Treatment
Liver Cancer SIG and Pediatric Liver Disorders SIG Program: Pediatric Liver Cancers: From Mechanisms to Treatment. PART 1: Mechanisms of Tumorigenesis
Open to view video.  |  91 minutes
Open to view video.  |  91 minutes This joint SIG Program is developed in collaboration by the Liver Cancer and Pediatric Liver Disorders SIGs in an effort to highlight state of the art research eludicating multiple pathways of the paticcarcinogenesis and how these findings have informed the selection of established and emerging medical therapies. Highlighting the program will be lectures on molecular and subtypes of pediatric liver tumors and their correlation with clinicohistopathologic features, mechanisms of treatment resistance in hepatoblastoma, current clinical guidelines in the treatment of pediatric liver cancer, novel therapeutic targets and patient/family priorities in their clinical care.
You must register to access.
Liver Cancer SIG and Pediatric Liver Disorders SIG Program: Pediatric Liver Cancers: From Mechanisms to Treatment. PART 2: Improving Treatment
Open to view video.  |  94 minutes
Open to view video.  |  94 minutes This joint SIG Program is developed in collaboration by the Liver Cancer and Pediatric Liver Disorders SIGs in an effort to highlight state of the art research eludicating multiple pathways of the paticcarcinogenesis and how these findings have informed the selection of established and emerging medical therapies. Highlighting the program will be lectures on molecular and subtypes of pediatric liver tumors and their correlation with clinicohistopathologic features, mechanisms of treatment resistance in hepatoblastoma, current clinical guidelines in the treatment of pediatric liver cancer, novel therapeutic targets and patient/family priorities in their clinical care.
You must register to access.
Alcohol-associated Liver Disease SIG and Nonalcoholic Fatty Liver Disease SIG Program: NAFLD and ALD: Similarities, Differences, and Learning Objectives: Targets, Treatments and Outcomes
Alcohol-associated Liver Disease SIG and Nonalcoholic Fatty Liver Disease SIG Program: NAFLD and ALD: Similarities, Differences, and Learning Opportunities. PART 1: Mechanisms, Risk Factors and Biomarkers
Open to view video.  |  91 minutes
Open to view video.  |  91 minutes
You must register to access.
Alcohol-associated Liver Disease SIG and Nonalcoholic Fatty Liver Disease SIG Program: NAFLD and ALD: Similarities, Differences, and Learning Objectives: Targets, Treatments and Outcomes. PART 2
Open to view video.  |  90 minutes
Open to view video.  |  90 minutes
You must register to access.
ACLF SIG and Clinical Practice SIG Program: State of the Art Management of Acute‐on‐Chronic Liver Failure
ACLF SIG and Clinical Practice SIG Program: State of the Art Management of Acute‐on‐Chronic Liver Failure. PART 1
Open to view video.
Open to view video. This joint program between the clinical practice and acute-on-chronic liver failure special interest groups will discuss the clinical management of the ACLF syndrome. In the first session, the symposium will introduce the concept of ACLF and the differences between ACLF and decompensated cirrhosis, followed by an evidence based discussions of the management of sepsis and acute kidney injury in the setting of ACLF. The second session will focus on the management of patients with severe ACLF who are often critically ill. Topics to be covered including management of bleeding, assessment of skeletalmuscle health, futility of liver transplantation and having end-of-life care discussion.
You must register to access.
ACLF SIG and Clinical Practice SIG Program: State of the Art Management of Acute‐on‐Chronic Liver Failure. PART 2
Open to view video.
Open to view video. This joint program between the clinical practice and acute-on-chronic liver failure special interest groups will discuss the clinical management of the ACLF syndrome. In the first session, the symposium will introduce the concept of ACLF and the differences between ACLF and decompensated cirrhosis, followed by an evidence based discussions of the management of sepsis and acute kidney injury in the setting of ACLF. The second session will focus on the management of patients with severe ACLF who are often critically ill. Topics to be covered including management of bleeding, assessment of skeletalmuscle health, futility of liver transplantation and having end-of-life care discussion
You must register to access.
Public Health/ Health Care Delivery SIG Program: Dissemination and Implementation Research: Conceptual Framework and Applications in Hepatology
Public Health/ Health Care Delivery SIG Program: Dissemination and Implementation Research: Conceptual Framework and Applications in Hepatology
Open to view video.
Open to view video. Dissemination and Implementation Science (D&I) is an emerging field focused on the science of improving the adoption and sustainment of evidence-based practices, programs, and interventions. The existing time-lag between research generation and actual bedside implementation results in low-value, inequitable healthcare. This session aims to introduce D&I as a discipline with tools and concepts that can accelerate the translation of hepatology research into practice.
You must register to access.
Pediatric Liver Disorders SIG Program: The Many Faces of Wilson Disease and Emerging Therapies
Pediatric Liver Disorders SIG Program: The Many Faces of Wilson Disease and Emerging Therapies
Open to view video.
Open to view video. This program is intended to make the audience aware of the role that ATP7B gene plays in copper metabolism in healthy individuals as well as those with WD, and also explore the role of epigenetics to help unravel the lack of genotype phenotype correlation. Using case studies, the speakers will highlight common as well as more subtle manifestations of WD, to facilitate early diagnosis and improve outcomes; and provide guidance on management of WD in pregnancy. Finally, management of WD that does not respond to standard therapy as well as current trials including genetherapy will be discussed
You must register to access.
Hepatotoxicity SIG Program: Gut Microbiota and Drug-Induced Liver Injury-Basic Mechanisms and Clinical Applications
Hepatotoxicity SIG Program: Gut Microbiota and Drug-Induced Liver Injury-Basic Mechanisms and Clinical Applications
Open to view video.
Open to view video. Recent emerging evidence has implicated the gut microbiota on drug metabolisms, drug efficacy and toxicity. This program will include both basic and physician scientists to cover the basic and clinic relevant topics on how microbiota would affect drug metabolism and hepatotoxicity as well as how manipulate microbiota or their metabolites would improve drug-induced liver injury. The program should attract basic researchers and clinician as well as postdoc trainees.
You must register to access.
Hepatology Associates SIG Program: Surgical Risk Stratification in Patients with Cirrhosis
Hepatology Associates SIG Program: Surgical Risk Stratification in Patients with Cirrhosis
Open to view video.  |  92 minutes
Open to view video.  |  92 minutes Surgical risk in patients with cirrhosis depend upon disease severity, type of surgical procedure, medical therapy optimization and operative management strategies.This program will cover each of these components through a 4-talk series followed by a panel discussion. This comprehensive session will provide an overview of key management considerations related to surgery and provide strategies for healthcare providers (teams?) to overcome the challenges commonly faced when considering surgery in the cirrhotic population
You must register to access.
Cholestatic & Autoimmune Liver Diseases SIG and Liver Transplant & Surgery SIG Program: Optimizing Pre- and Post-Transplant Management of Immune Mediated Liver Disease
Cholestatic & Autoimmune Liver Diseases SIG and Liver Transplant & Surgery SIG Program: Optimizing Pre- and Post-Transplant Management of Immune Mediated Liver Disease. PART 1: Pre-Transplant Management of Immune Mediated Liver Disease
Open to view video.
Open to view video. Examine the evolving epidemiology, pre- and posttransplant management of immune mediated liver diseases and their complications by integrating current evidence-based practice in pre-transplant clinical care, advances in diagnostic and management techniques, and state-of-the-art management.
You must register to access.
Cholestatic & Autoimmune Liver Diseases SIG and Liver Transplant & Surgery SIG Program: Optimizing Pre- and Post-Transplant Management of Immune Mediated Liver Disease. PART 2
Open to view video.  |  90 minutes
Open to view video.  |  90 minutes
You must register to access.
Portal Hypertension SIG Program: Microbiota, Cirrhosis and Portal Hypertension
Portal Hypertension SIG Program: Microbiota, Cirrhosis and Portal Hypertension
Open to view video.  |  91 minutes
Open to view video.  |  91 minutes Come learn and engage in discussion about the clinical implications of the Liver-Gut Axis. This SIG program will explore the mechanistic underpinnings and clinical relevance of the connections between the microbiome, cirrhosis and portal hypertension.
You must register to access.
Liver Fibrosis SIG and Liver Cell Biology SIG Program: Metabolic Reprogramming of Liver Cells as a Driving Force in Liver Fibrosis
Liver Fibrosis SIG Liver Cell Biology SIG Program: Metabolic Reprogramming of Liver Cells as a Driving Force in Liver Fibrosis. PART 1
Open to view video.  |  82 minutes
Open to view video.  |  82 minutes This joint SIG program, organized by Liver Cell Biology and Liver Fibrosis SIGs, is focusing around evolving understanding that metabolic derangements in liver cells are important drivers of disease and fibrosis in particular. First part of the session will set the stage with general overview of new data on metabolic changes at the organ level and in hepatocytes, as a specialized metabolic cell. In the second part, audience will learn about recent discoveries on specific metabolic reprograming in non-parenchymal cells, metabolism of which until recently was not recognized as a functional modulator of liver fibrosis.
You must register to access.
Liver Fibrosis SIG and Liver Cell Biology SIG Program: Metabolic Reprogramming of Liver Cells as a Driving Force in Liver Fibrosis. PART 2
Open to view video.
Open to view video. This joint SIG program, organized by Liver Cell Biology and Liver Fibrosis SIGs, is focusing around evolving understanding that metabolic derangements in liver cells are important drivers of disease and fibrosis in particular. First part of the session will set the stage with general overview of new data on metabolic changes at the organ level and in hepatocytes, as a specialized metabolic cell. In the second part, audience will learn about recent discoveries on specific metabolic reprograming in non-parenchymal cells, metabolism of which until recently was not recognized as a functional modulator of liver fibrosis.
You must register to access.
Hepatitis C SIG Program: Remaining Challenges and Opportunities in Hepatitis C Prevention and Treatment
Hepatitis C SIG Program: Remaining Challenges and Opportunities in Hepatitis C Prevention and Treatment
Open to view video.
Open to view video. Despite unprecedented advances in the diagnosis and management of people with hepatitis C virus, substantial challenges remain to the elimination of hepatitis C as a public health threat and the prevention and treatment of hepatitis C virus infection in particular patient populations who remain underserved by current care strategies. In this Hepatitis C SIG program, our experts will discuss the challenges and opportunities to address the threat of hepatitis in people who use drugs, those who are pregnant, and persons who have received disparate care as a result of racial and ethnic inequities.
You must register to access.